Idazoxan XR is under clinical development by Terran Biosciences and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Idazoxan XR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Idazoxan XR overview

Idazoxan XR is under development for the treatment of schizophrenia and unspecified neuropsychiatric disorders. The drug candidate is administered through oral route and acts by targeting alpha 2-adrenoceptor. It is being developed based on AI-enabled imaging software platform.

Terran Biosciences overview

Terran Biosciences discover and develops next-generation therapeutics to treat neurological and psychiatric disorders. The company’s smart clinical development platform utilizes diagnostics and predicative technologies for therapeutic development process. It is investigating its lead program TR-01 targeting schizophrenia and TR-36 against depression. Terran Biosciences medical device program helps in transforming late-stage clinical therapeutic of pre-clinical assets with multiple leads. Terran Biosciences is headquartered in New York City, New York, the US.

For a complete picture of Idazoxan XR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.